Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome

Does daily myo-inositol supplementation reduce the risk of a composite outcome of gestational diabetes, preeclampsia, or preterm birth in pregnant individuals with polycystic ovary syndrome (PCOS) compared with placebo?This double-blind, placebo-controlled, multicenter randomized trial included 464 pregnant individuals with PCOS. The prevalence of the primary composite outcome consisting of gestational diabetes, preeclampsia, and preterm birth was 25.0% in those randomized to receive myo-inositol and 26.8% in those randomized to receive placebo, which was a nonsignificant difference.Daily myo-inositol supplementation during pregnancy for individuals with PCOS is not recommended to reduce gestational diabetes, preeclampsia, and preterm birth compared with placebo.

Corresponding Author: Anne W. T. van der Wel, MD, Department of Obstetrics and Gynecology, Amsterdam Reproduction a.vanderwel@amsterdamumc.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.